Plasmodium Immunotherapy for Advanced Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

March 31, 2023

Study Completion Date

July 31, 2026

Conditions
Advanced Cancers
Interventions
BIOLOGICAL

Blood-stage infection of P.vivax

The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.

Trial Locations (1)

510000

RECRUITING

Guangzhou Fuda Tumor Hospital, Guangzhou

All Listed Sponsors
lead

CAS Lamvac Biotech Co., Ltd.

INDUSTRY